Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  American Journal of Pathology

• Publication date

  1996-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8644856PMCID PMC1861510
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Membrane proteins that protect against complement lysis

  2005cited by this paper
• Expression and function of CD59 on colonic adenocarcinoma cells

  1994cited by this paper
• RNA expression of complement regulatory proteins in human brain tumors.

  1994cited by this paper
• The expression of CD59 in normal human nervous tissue.

  1994cited by this paper
• Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.

  1994cited by this paper
• Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells

  1994cited by this paper
• Identification and quantification of complement regulator CD46 on normal human tissues.

  1993cited by this paper
• Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes.

  1993cited by this paper
• Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells.

  1993cited by this paper
• Regulation of CD59 expression on the human endothelial cell line EA.hy 926

  1993cited by this paper
• Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement.

  1993cited by this paper
• Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.

  1993cited by this paper
• Clusterin: the intriguing guises of a widely expressed glycoprotein.

  1992cited by this paper
• Expression of complement components of the alternative pathway by glioma cell lines.

  1992cited by this paper
• Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.

  1991cited by this paper
• Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.

  1991cited by this paper
• Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death.

  1991cited by this paper
• Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

  1990cited by this paper
• CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

  1989cited by this paper
• Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

  1989cited by this paper
• Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

  1989cited by this paper
• Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets.

  1989cited by this paper
• Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.

  1988cited by this paper
• Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

  1988cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Preliminary clinical trial of immunotherapy for malignant glioma.

  1987cited by this paper
• Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.

  1986cited by this paper
• Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b

  1986cited by this paper
• Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

  1982cited by this paper
• Protein determination in membrane and lipoprotein samples: manual and automated procedures.

  1981cited by this paper
• Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

  1979cited by this paper

• Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review)

  2025cites this paper
• An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas

  2024cites this paper
• Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy

  2024cites this paper
• A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma

  2022cites this paper
• Pathological Characteristics of Echovirus 30 Infection in a Mouse Model

  2022cites this paper
• Modulation of the Complement System by Neoplastic Disease of the Central Nervous System

  2021influential citation
• Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.

  2021cites this paper
• CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity

  2021cites this paper
• Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes

  2021cites this paper
• GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma

  2020cites this paper
• Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma

  2020cites this paper
• Expression of Tumor Microenvironment Related Molecules C4d, Hsp27, Polysialic Acid and NCAM in Astrocytic Gliomas

  2017cites this paper
• Characterisation of glioblastoma subtypes: implications for therapy resistance

  2016cites this paper
• Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy

  2015cites this paper
• Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.

  2014cites this paper
• Low pathogenic human enteroviruses as novel anti-cancer agents against malignant glioma

  2014influential citation
• CD 59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells

  2013cites this paper
• CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells.

  2013cites this paper
• A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery.

  2012cites this paper
• A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy.

  2012cites this paper
• Complement activation in astrocytomas: deposition of C4d and patient outcome

  2012cites this paper
• State-ofthe-Art Paper Vox Sanguinis S

  2011cites this paper
• Lymphocytesof Cytolytic Effector Surface Topographies That Resist the Glioma Cells Display Complex Cell

  2010cites this paper
• Cytolytic Effector Lymphocytes Topographies That Resist the Actions of Glioma Cells Display Complex Cell Surface

  2010cites this paper
• Glioma Cells Display Complex Cell Surface Topographies That Resist the Actions of Cytolytic Effector Lymphocytes

  2010cites this paper
• Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

  2008cites this paper
• Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas

  2008cites this paper
• Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity.

  2008cites this paper
• Downregulation of CD46 During Muscle Differentiation: Implications for Gene Transfer to Human Skeletal Muscle Using Group B Adenoviruses

  2008cites this paper
• Oncolytic measles virus strains in the treatment of gliomas

  2008cites this paper
• Characterization of infectivity of knob-modified adenoviral vectors in glioma

  2008cites this paper
• Resistance Mechanisms of Non-Hodgkin Lymphomas against Rituximab Treatment

  2007cites this paper
• Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.

  2007cites this paper
• Fiber‐knob modifications enhance adenoviral tropism and gene transfer in malignant glioma

  2007cites this paper
• CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma

  2007cites this paper
• Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.

  2007cites this paper
• Control of complement activation by cancer cells and its implications in antibody-mediated cancer immunotherapy

  2006cites this paper
• Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.

  2006cites this paper
• The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy

  2006cites this paper
• Complement decay accelerating factor (DAF)/CD55 in cancer

  2006cites this paper
• CD46 Represents a Target for Adenoviral Gene Therapy of Malignant Glioma

  2006cites this paper
• Determinants of Glioma: An epidemiological and genetic study

  2006cites this paper
• Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy

  2005cites this paper
• Tumor Cell Resistance to Complement-Mediated Lysis

  2004cites this paper
• Expression of Complement Factor H by Lung Cancer Cells

  2004cites this paper
• Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Cleaves C3b, an Essential Component of the Complement System*

  2004cites this paper
• Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer

  2004cites this paper
• Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

  2003cites this paper
• Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

  2003cites this paper
• A sensitive flow cytometry method for anti-GM1 antibodies detection.

  2002cites this paper
• Activation of Leukocytes During the Uteroplacental Passage in Preeclampsia

  2002cites this paper
• The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies

  2002cites this paper
• Complement resistance mechanisms of human tumor cells

  2002cites this paper
• Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma.

  2001cites this paper
• A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage

  2000cites this paper
• Targeting of cancer cells with monoclonal antibodies specific for C3b(i)

  2000cites this paper
• Factor H and Factor H-Like Protein 1 Killing by Expression and Utilization of Glioblastoma Cells to Complement-Mediated Exceptional Resistance of Human H 2 Zipfel

  2000influential citation
• Exceptional Resistance of Human H2 Glioblastoma Cells to Complement-Mediated Killing by Expression and Utilization of Factor H and Factor H-Like Protein 11

  2000influential citation
• Free radicals in gliomas: friend or foes?

  1999cites this paper
• Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer

  1999cites this paper
• Expression of membrane cofactor protein (MCP, CD46) in human liver diseases

  1999cites this paper
• Complement resistance of tumor cells: basal and induced mechanisms.

  1999cites this paper
• Commentary: Free radicals in gliomas: friend or foes?

  1999cites this paper
• Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies

  1999cites this paper
• Immune evasion of tumor cells using membrane-bound complement regulatory proteins.

  1999cites this paper
• FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated.

  1999cites this paper
• Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells.

  1999cites this paper
• Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.

  1998cites this paper
• Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).

  1998cites this paper
• Complement Regulation

  1998cites this paper
• A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.

  1998cites this paper
• Tumor Cell Lysis by Complement Antigen G250 Enhances C3 Deposition and Regulator CD55 and the Renal Tumor-Associated Against Both the Membrane-Bound Complement A Bispecific Monoclonal Antibody Directed

  1998cites this paper
• Up‐regulated expression of decay‐accelerating factor (CD55) confers increased complement resistance to sprouting neural cells

  1998cites this paper
• Complement-mediated killing of microtumors in vitro.

  1998cites this paper
• Complement‐regulatory proteins in ovarian malignancies

  1997cites this paper
• Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

  1997cites this paper
• Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

  1997cites this paper
• Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer

  1997cites this paper
• Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).

  1997cites this paper